CDC25B and hepatocellular carcinoma: Previous studies have demonstrated that cell cycle regulation can synergize with chemotherapy in both promotion and inhibition [19, 20].Therefore, we investigated the relationship between CDC25B expression and sensitivity to some drugs as well as immune checkpoints, and we found that in HCC patients with high expression of CDC25B, their sensitivity to cisplatin, sorafenib, cytarabine, fludarabine, and axitinib was significantly reduced.